#ES­MO22: At five-year mark, Lyn­parza kept more pa­tients alive than Avastin but missed over­all OS sig­nif­i­cance

PARIS — As­traZeneca and Mer­ck ar­rived at ES­MO with long-term da­ta on their block­buster can­cer drug and Eu­ro­pean con­fab sta­ple Lyn­parza, which ush­ered in the PARP …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER